Spots Global Cancer Trial Database for estrogen receptor positive breast cancer
Every month we try and update this database with for estrogen receptor positive breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | NCT04443348 | Triple Negative... Hormone Recepto... Biopsy-proven, ... | Radiation Thera... Pembrolizumab Paclitaxel Carboplatin Cyclophosphamid... Doxorubicin Capecitabine | 18 Years - | Massachusetts General Hospital | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | NCT02947685 | HER-2 Positive ... Estrogen Recept... | palbociclib trastuzumab pertuzumab letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | Alliance Foundation Trials, LLC. | |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer | NCT02392611 | Solid Tumors an... | Alobresib Exemestane Fulvestrant | 18 Years - | Gilead Sciences | |
| Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor | NCT01765049 | Invasive Breast... Estrogen Recept... | - 70 Years | Seoul National University Hospital | ||
| A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) | NCT02000375 | Metastatic Brea... Estrogen Recept... Estrogen Recept... Progesterone Re... Progesterone Re... Androgen Recept... | DHEA | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older | NCT02823262 | Breast Cancer Estrogen Recept... Node-negative B... Human Epidermal... | Breast Cancer T... Usual Care | 70 Years - | Beth Israel Deaconess Medical Center | |
| A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) | NCT02000375 | Metastatic Brea... Estrogen Recept... Estrogen Recept... Progesterone Re... Progesterone Re... Androgen Recept... | DHEA | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy | NCT01984138 | Estrogen Recept... Breast Cancer | ESTRING Replens | 18 Years - | The Methodist Hospital Research Institute | |
| A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older | NCT02823262 | Breast Cancer Estrogen Recept... Node-negative B... Human Epidermal... | Breast Cancer T... Usual Care | 70 Years - | Beth Israel Deaconess Medical Center | |
| Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy | NCT02414776 | Estrogen Recept... | hydroxychloroqu... | 18 Years - | Western Regional Medical Center | |
| Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor | NCT01765049 | Invasive Breast... Estrogen Recept... | - 70 Years | Seoul National University Hospital | ||
| Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | NCT02820961 | Breast Cancer Estrogen Recept... | entinostat exemestane | 18 Years - 85 Years | Syndax Pharmaceuticals | |
| FES-PET for Patients Treated on NCI Protocol 8762 | NCT01714128 | Breast Cancer | Diagnostic Imag... | 18 Years - | Washington University School of Medicine | |
| A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene | NCT01219699 | Advanced Solid ... Estrogen Recept... | BYL719 Fulvestrant | 18 Years - | Novartis | |
| A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene | NCT01219699 | Advanced Solid ... Estrogen Recept... | BYL719 Fulvestrant | 18 Years - | Novartis | |
| A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers | NCT02238808 | Estrogen Recept... | Estradiol | 55 Years - | AHS Cancer Control Alberta | |
| REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy | NCT01984138 | Estrogen Recept... Breast Cancer | ESTRING Replens | 18 Years - | The Methodist Hospital Research Institute | |
| FES-PET for Patients Treated on NCI Protocol 8762 | NCT01714128 | Breast Cancer | Diagnostic Imag... | 18 Years - | Washington University School of Medicine | |
| Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer | NCT01992952 | Estrogen Recept... | AZD5363 Placebo Fulvestrant | 18 Years - | Velindre NHS Trust | |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer | NCT02392611 | Solid Tumors an... | Alobresib Exemestane Fulvestrant | 18 Years - | Gilead Sciences | |
| Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer | NCT04631835 | Breast Cancer | HS-10352 | 18 Years - 75 Years | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy | NCT01984138 | Estrogen Recept... Breast Cancer | ESTRING Replens | 18 Years - | The Methodist Hospital Research Institute | |
| Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer | NCT04631835 | Breast Cancer | HS-10352 | 18 Years - 75 Years | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
